Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging

Mediastinal Tumor Clinical Trial

Official title:

Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03214341
• Other study ID #: MRIML
• Status: Not yet recruiting
• Phase: N/A
• First received: June 24, 2017
• Last updated: July 10, 2017
• Start date: December 1, 2017
• Est. completion date: December 30, 2019

Study information

• Verified date: July 2017
• Source: Assiut University
• Contact: Noha Mohammed Ali Attia, lecturer
• Phone: 00201001238435
• Email: nohamohammedali[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy which is essential for treatment planning as well as for prognosis

Description:

Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy is essential for treatment planning as well as for prognosis .

MRI presents valuable diagnostic information in assessing the mediastinum. In addition, special applications have been developed over recent years diffusion-weighted magnetic resonance imaging is one such technique The advent of echo-planar imaging technique has rendered diffusion weighted imaging of the abdomen and thoracic cavity possible .

Quantitative assessment of the mediastinal mass is possible by calculation of apparent diffusion co-efficient value ,which is related to the proportion of extracellular and intracellular component.

The apparent diffusion co-efficient is inversely correlated with tissue cellularity. It is lower in viable tumor tissue with densely packed diffusion-hindering obstacles than in tissue with less densely packed obstacles such as tumor necrosis and benign tissue .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: December 30, 2019
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Any age groups

• diagnosis of mediastinal mass (by Multislice Computed Tomography).

Exclusion Criteria:

• chemotherapy radiotherapy.

• thoracic surgery.

• cystic mass .

• mass with large amount of necrosis or calcification.

• contraindication of MRI (e.g. pacemakers , claustrophobia).

Related Conditions & MeSH terms

• Mediastinal Neoplasms
• Mediastinal Tumor

Intervention

Radiation:
• MRI diffusion
using MRI diffusion to differentiate between benign and malignant mediastinal masses

Locations

Country	Name	City	State
Egypt	Assiut university	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	sensitivity and specificity of magnetic resonance imaging diffusion in mediastinal masses		up to one month

External Links

•   the investigator had gained some information from this site